Payment overview · 2025
General Payments
$1,352.54
72 reported records · 23 companies
Healthcare provider profile · identity verified
Michael Patrick Roberts, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NICEVILLE, FL · NPI 1972691368
Verified facts
What the public records show
CMS Open Payments records show Michael Patrick Roberts, M.D. received $1,352.54 in general payments during 2025 across 72 reported records.
Amgen Inc. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $176.55 | 13.1% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.32 | 12.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.08 | 11.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.23 | 8.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.49 | 7.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.18 | 7.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $66.09 | 4.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.15 | 4.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.33 | 4.2% | 2 | 2025 |
| McKesson Medical-Surgical, Inc. | Unresolved — no canonical attribution shown | $50.14 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.26 | 3.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.91 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.38 | 2.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.24 | 2.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.34 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.13 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.02 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.84 | 1.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.15 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.62 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,352.54 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $163.22 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.30 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.23 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.54 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.54 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.18 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $75.01 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.72 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $66.09 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.15 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.80 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.24 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 123 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
123 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 39 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 609 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 157 |
| Omeprazole | Omeprazole | 477 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 121 |
| Lisinopril | Lisinopril | 332 | 103 |
| Losartan Potassium | Losartan Potassium | 328 | 98 |
| Simvastatin | Simvastatin | 294 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 78 |
| Gabapentin | Gabapentin | 257 | 72 |
| Furosemide | Furosemide | 253 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 58 |
| Alprazolam | Alprazolam | 212 | 67 |
| Eliquis | Apixaban | 203 | 39 |
| Meloxicam | Meloxicam | 180 | 55 |
| Trazodone Hcl | Trazodone Hcl | 179 | 49 |
| Tramadol Hcl | Tramadol Hcl | 173 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 46 |
| Potassium Chloride | Potassium Chloride | 159 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 58 |
| Metformin Hcl | Metformin Hcl | 149 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 42 |
| Ozempic | Semaglutide | 124 | 32 |
| Mounjaro | Tirzepatide | 123 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 36 |
| Azithromycin | Azithromycin | 108 | 87 |
| Carvedilol | Carvedilol | 108 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 47 |
| Montelukast Sodium | Montelukast Sodium | 103 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 44 |
| Celecoxib | Celecoxib | 95 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 26 |
| Sertraline Hcl | Sertraline Hcl | 81 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 20 |
| Lorazepam | Lorazepam | 78 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 24 |
| Ezetimibe | Ezetimibe | 77 | 24 |
| Pregabalin | Pregabalin | 76 | 24 |
| Allopurinol | Allopurinol | 75 | 29 |
| Jardiance | Empagliflozin | 70 | 23 |
| Metformin Hcl Er | Metformin Hcl | 70 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 26 |
| Methylprednisolone | Methylprednisolone | 67 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 14 |
| Atenolol | Atenolol | 63 | 14 |
| Glipizide | Glipizide | 62 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 16 |
| Spironolactone | Spironolactone | 58 | 23 |
| Baclofen | Baclofen | 56 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 41 |
| Buspirone Hcl | Buspirone Hcl | 54 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 16 |
| Sucralfate | Sucralfate | 54 | 14 |
| Prednisone | Prednisone | 53 | 30 |
| Xarelto | Rivaroxaban | 52 | 13 |
| Clonidine Hcl | Clonidine Hcl | 51 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 15 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 16 |
| Estradiol | Estradiol | 49 | 17 |
| Famotidine | Famotidine | 49 | 18 |
| Methocarbamol | Methocarbamol | 49 | 14 |
| Alendronate Sodium | Alendronate Sodium | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Promethazine Hcl | Promethazine Hcl | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 47 | 14 |
| Ondansetron Odt | Ondansetron | 47 | 33 |
| Finasteride | Finasteride | 45 | 14 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 12 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Nifedipine Er | Nifedipine | 42 | 11 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 12 |
| Valsartan | Valsartan | 40 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 20 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 16 |
| Ibuprofen | Ibuprofen | 35 | 18 |
| Myrbetriq | Mirabegron | 35 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 15 |
| Entresto | Sacubitril/Valsartan | 34 | 11 |
| Diazepam | Diazepam | 33 | 14 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 13 |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Nitroglycerin | Nitroglycerin | 27 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 12 |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Colchicine | Colchicine | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,352.54 · 72 records | Amgen Inc. | AIRSUPRA, Auvelity, CAPLYTA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SIMPONI, SIMPONI ARIA, STELARA, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error